Declining System Sales Drag Cepheid Q1 Revenues Down 13 Percent
April 24, 2009
Declining System Sales Drag Cepheid Q1 Revenues Down 13 Percent
The company reported a 45 percent drop in system sales for the first quarter, but a 79 percent increase in sales of its clinical tests.
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.
New to GenomeWeb? Register here quickly for free access.
Related Stories
- Cepheid Highlights Strong Uptake of Xpert CT/NG as Q1 Revenues Rise 19 Percent
April 25, 2013 / PCR Insider - Cepheid Reports Q4, FY '12 Revenue Growth, but Looks to Address Issues from 'Challenging' Year
January 31, 2013 / PCR Insider - Cepheid Plans 1,000-Target PCR, Protein Detection, FFPE Analysis, Other Upgrades to GeneXpert
September 27, 2012 / PCR Insider - Cepheid Inks First in Series of Agreements to Buy Down Price of Xpert TB Test
August 9, 2012 / PCR Insider - Unitaid Provides $30M to Reduce Cost, Increase Uptake of Cepheid TB Test in Developing World
June 14, 2012 / PCR Insider